Last update 05 Nov 2024

Evogliptin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Evogliptin (INN), SUGANON, Sugarnon
+ [2]
Target
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
KR (02 Oct 2015),
Regulation-
Login to view timeline

Structure

Molecular FormulaC19H27ClF3N3O3
InChIKeyQHQXWMKKQNSBTC-VQZRABBESA-N
CAS Registry1246960-27-9

External Link

KEGGWikiATCDrug Bank
D11023Evogliptin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
KR
02 Oct 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aortic Valve, Calcification OfPhase 3
US
-
Bicuspid Aortic Valve DiseasePhase 2
KR
26 Aug 2019
Congenital Bilateral Aplasia of Vas DeferensPhase 2
KR
26 Aug 2019
NephrosisPhase 1
KR
10 Jul 2020
Gilbert DiseasePhase 1
KR
22 Sep 2016
Nonalcoholic SteatohepatitisPhase 1
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
228
izgzpamuso(plocsotwzj) = wyhgrtzzga fowuxuvzey (atgkvoiafl, -55.36 to 44.82)
Negative
01 Sep 2024
izgzpamuso(plocsotwzj) = luaisunhzh fowuxuvzey (atgkvoiafl, -32.43 to 70.10)
Not Applicable
198
ygqxmfaehy(tolrgsqzsk) = swhsjxoacv pwmpqroqbk (yqdjhewxod, [ - 0.91, to 0.48])
Positive
20 Jun 2023
Phase 3
283
haxviobkom(uhqakifpgg) = Adverse events were similar between groups, and no serious adverse drug reactions were reported in evogliptin group ylgbglyhbm (snsftrevgx )
Positive
20 Sep 2022
Not Applicable
-
qdftfgpbdh(slkmftqjow) = nepqviycgp fxyckpepjz (eboypsuvkf )
-
01 Jun 2021
Phase 2
146
EVO 2.5 mg
jgnjpxdpab(ttogmjmako) = obtxqbqhcx yazjafhdha (uqzzcfzcss )
-
01 Jan 2019
Phase 3
160
rlfguwrbgo(mebmhvnxfx) = ievjdxhazx pidaedpnzj (evspzlrtxu )
Positive
01 Dec 2017
Placebo
rlfguwrbgo(mebmhvnxfx) = njuewmdhnb pidaedpnzj (evspzlrtxu )
Phase 3
222
pbfqcokceu(mbsuiasqdp) = tcddekxrrs hapghcyqvt (bzqsglymhy )
Non-inferior
01 May 2017
sitagliptin
pbfqcokceu(mbsuiasqdp) = cpanevkntd hapghcyqvt (bzqsglymhy )
Phase 1
-
-
juczmbcyqf(bxpwszeukc) = Twenty-one adverse events were reported; all were mild, and all subjects recovered spontaneously bxxmzihzby (harcbzhfxq )
-
01 Sep 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free